|
Jan 2
|
Gannex Announces Positive Interim Results from 52-Week Phase II Clinical Trial of Once-Daily ASC41 Tablet in Patients with Biopsy-Confirmed Non-alcoholic Steatohepatitis
|
|
Dec 5
|
Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
|
|
Nov 13
|
Ascletis Announces Poster Presentations at AASLD Annual Meeting 2023 Including a Late-Breaking Abstract of Interim Results from Phase IIb Expansion Cohort of ASC22 for Functional Cure of CHB
|
|
Nov 9
|
Dr. Jinzi J. Wu Presents at the 10th International Workshop on HBV Cure 2023
|
|
Sep 5
|
Ascletis to Participate in the Upcoming Morgan Stanley 21st Annual Global Healthcare Conference
|
|
Jul 20
|
Gannex Announces the Completion of Patient Enrollment for Phase II Clinical Trial of ASC42, an FXR Agonist, for Primary Biliary Cholangitis
|